Nebula inks its first pharma partnership with Merck Serono to develop treatment for lung cancer

August 06, 2019 | Case Study

The consumer genomics space has been rife with concerns about data ownership, usage, privacy, and security. From companies getting hacked to ones profiting from consumer data without notice or compensation, consumers have become more concerned about having their genomes sequenced. This unfortunately means that pharmaceutical developers face limited access to large genomic datasets, which is critical for the development of targeted treatments. Nebula Genomics offers a solution that resolves the matter for both parties (consumers and companies) by building a marketplace around genomic data on a blockchain platform. Merck Serono plans to leverage Nebula's platform to develop personalized lung cancer treatments in this recently announced partnership.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978